evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

109 questions · 112 findings · 3 reviews · Kidney and Transplant

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 26 · 23.2%GRADE not reported 1 · 0.9%Very low 10 · 8.9%Low 50 · 44.6%Moderate 25 · 22.3%High 0 · 0%

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Anuria · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in anuria compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Non‐fatal cardiovascular events · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular events (non‐fatal) compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Cough · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in cough compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Hyperkalaemia · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in hyperkalaemia compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in fatal or nonfatal myocardial infarction Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease

Angiotensin receptor blockers may leads to lower micro‐ to macroalbuminuria Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin receptor blockers changes micro‐ to normoalbuminuria Median compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs another ARB

Death (all causes) · people with diabetes and kidney disease

It is very uncertain whether angiotensin receptor blocker (ARB) changes all‐cause death Median compared with another ARB (very low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs another ARB

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin receptor blocker (ARB) showed no clear difference in fatal or nonfatal myocardial infarction7 compared with another ARB (low certainty).

1 finding from 1 review